ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ЭНОКСАПАРИНА ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕ
Аннотация
В данной статье обсуждаются возможности использования эноксапарина при остром коронарном синдроме (ОКС). Подробно рассматриваются вопросы эффективности и безопасности эноксапарина при ОКС как с подъемом сегмента ST (в т. ч. в зависимости от реперфузионной стратегии), так и без подъема ST, а также основные моменты, на которые следует обратить внимание при лечении эноксапарином (лабораторный контроль, нарушение функции почек, масса тела, смена антикоагулянта в процессе лечения, пожилой возраст).
Об авторе
Н. М. Воробьеева
ФГБОУ ВО «Российский научно-исследовательский медицинский университет им. Н.И. Пирогова» МЗ РФ; Российский геронтологический научно-клинический центр, г. Москва
Россия
д.м.н.
Россия
д.м.н.
Список литературы
1. Murphy SA, Gibson CM, Morrow DA et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J, 2007, 28: 2077–2086.
2. Giraldez RR, Nicolau JC, Corbalan R et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACTTIMI 25 analysis. Eur Heart J, 2007, 28: 1566–1573.
3. Sabatine MS, Morrow DA, Dalby A et al., for the ExTRACT-TIMI 25 Investigators. Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel. JACC, 2007, 49: 2256–2263.
4. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012, 33: 2569–2619.
5. Antman EM, Morrow DA, McCabe CH et al., for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. N Engl J Med, 2006, 354: 1477–1488.
6. Antman EM, Morrow DA, McCabe CH et al., for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J, 2005, 149: 217–226.
7. Gibson CM, Murphy SA, Montalescot G et al., for the ExTRACT-TIMI 25 Investigators. Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial. JACC, 2007, 49: 2238–2246.
8. Silvain J, Beygui F, Barthelemy O et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. Br Med J, 2012, 344: e553.
9. Montalescot G, Ellis SG, de Belder MA et al. Enoxaparin in primary and facilitated percutaneous coronary intervention. A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv, 2010, 3: 203–212. _
10. Navarese EP, De Luca G, Castriota F et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost, 2011, 9: 1902–1915.
11. Montalescot G, Zeymer U, Silvain J et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet, 2011, 378: 693–703.
12. Wiviott SD, Braunwald E., McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357: 2001–2015.
13. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361: 1045–1057.
14. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, 2009, 373: 723–731.
15. Cohen M, Gensini GF, Maritz F et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. JACC, 2003, 42: 1348–1356.
16. Antman E, McCabe C, Gurfinkel E et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation, 1999,100: 1593–1601.
17. Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA, 2004, 292: 45–54.
18. Collet JP, Montalescot G, Lison L et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation, 2001, 103: 658–663.
19. Martin JL, Fry ET, Sanderink GJ et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv, 2004, 61: 163–170.
20. Murphy SA, Gibson CM, Morrow DA et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J, 2007, 28: 2077–2086.
21. Silvain J, Beygui F, Barthelemy O et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ, 2012, 344 : 553.
22. Roffi M, Patrono C, Collet J-P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016, 37: 267–315.
23. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2): 24–43.
24. Linkins L-A, Dans AL, Moores LK et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141: 495–530.
25. Fox KAA, Bassand J-P, Mehta SR et al on behalf of the OASIS 5 Investigators. Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndromes. Ann Intern Med, 2007, 147: 304–310.
26. Fox KAA., Antman EM, Montalescot G et al. The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial. JACC, 2007, 49: 2249–2255.
27. Alexander KP, Chen AY, Roe MT et al for the CRU-SADE Investigators. Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST Segment Elevation Acute Coronary Syndromes. JAMA, 2005, 294: 3108–3116.
28. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. JACC, 1997, 29: 1474–1482.
29. The SYNERGY Trial Investigators. Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. Primary Results of the SYNERGY Randomized Trial. JAMA, 2004, 292: 45–54.
30. Cohen M, Mahaffey KW, Pieper K et al on behalf of the SYNERGY Trial Investigators. A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. JACC, 2006, 48: 1346–1354.
31. Petersen JL, Mahaffey KW, Hasselblad V et al. Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes. A Systematic Overview. JAMA, 2004, 292: 89–96.
32. Lopes RD, Alexander KP, Marcucci G et al. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Eur Heart J, 2008, 29: 1827–1833.
33. Armstrong PW, Chang WC, Wallentin L et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ, 2006, 174: 1421–1426.
34. Thomas D, Giugliano RP. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. J Thromb Thrombolysis, 2009, 27: 1–10.
35. Andreotti F, Rocca B, Husted S et al., on behalf of the ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J, 2015, 36: 3238–3249.
Для цитирования:
Воробьеева Н.М. ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ЭНОКСАПАРИНА ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕ. Атеротромбоз. 2016;(2):36-45. https://doi.org/10.21518/2307-1109-2016-2-36-45
Просмотров: 413
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Послать статью по эл. почте 